DACH

Beekeeper Study Finds Nearly 50% of Frontline Workers Changed Jobs in 2023

Retrieved on: 
Wednesday, January 17, 2024
Software, Human Resources, Professional Services, Technology, Apps, Applications, Fintech, Mobile, Wireless, Business, Learning, Morale, DACH, Heart, Front line, Trust, Multimedia, Communication, Environment, Head Office, Great Migration, Human, Management

View the full release here: https://www.businesswire.com/news/home/20240117733401/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240117733401/en/
    Key findings from Beekeeper's Frontline Workforce Pulse Report (Graphic: Business Wire)
    The report suggests a growing disconnect between frontline workers and management, leading to increased disengagement among frontline workers.
  • "The pandemic may be in the rearview, but the problems it created for frontline workers haven't gone anywhere," said Cristian Grossmann, Beekeeper CEO and co-founder.
  • "Turnover rates remain alarmingly high across industries, with frontline workers feeling overstressed, undervalued, and often unheard by management.
  • Per the report, the daily challenges facing frontline workers have worsened significantly in the years since the pandemic.

Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders - Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised

Retrieved on: 
Tuesday, January 23, 2024
DACH, Corporate services, Traction, Health care, Permira, Intelligence, Business, ESG, TA Associates, Acquisition, Appetite, The Access Group, Bank

The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.

Key Points: 
  • The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.
  • Additionally, the report explores overall deal flow in 2023 and lender activity in ESG-related deals.
  • European direct lending activity in 2023 totalled 680 deals with lower mid-market deals by far the most popular debt range, representing 80.5% of the market.
  • Unitranche deals dominated the market, making up 71.1% of the deals seen in 2023.

Ares, Eurazeo, Barings Among Top 2023 European Direct Lenders - Lower Mid Market Deals Account for 80% of Transactions Despite Record Unitranche Size Raised

Retrieved on: 
Tuesday, January 23, 2024
DACH, Corporate services, Traction, Health care, Permira, Intelligence, Business, ESG, TA Associates, Acquisition, Appetite, The Access Group, Bank

The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.

Key Points: 
  • The league tables rank European direct lender activity in 2023 across factors including region and sub-region, loan size and sector.
  • Additionally, the report explores overall deal flow in 2023 and lender activity in ESG-related deals.
  • European direct lending activity in 2023 totalled 680 deals with lower mid-market deals by far the most popular debt range, representing 80.5% of the market.
  • Unitranche deals dominated the market, making up 71.1% of the deals seen in 2023.

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024
Digital health, Sleep, PSG, DACH, Health, Partnership, BOM, ONERA, American Academy, Medicine, Generative grammar, Medtech, Polysomnography, AASM, Growth, Pharmaceutical industry

Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.

Key Points: 
  • Onera Health, a leader in sleep diagnostic and monitoring solutions, closed a €30M ($32M) Series C financing round.
  • Eindhoven – January 16, 2024 – Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

Onera raises over €30M in Series C funding

Retrieved on: 
Tuesday, January 16, 2024
Software, General Health, Mobile, Wireless, Hardware, Biometrics, Technology, Medical Devices, Health Technology, Nanotechnology, Neurology, Biotechnology, Wearables, Mobile Technology, Health, Digital health, Sleep, PSG, DACH, Multimedia, Partnership, BOM, ONERA, American Academy, Medicine, Generative grammar, Medtech, Polysomnography, AASM, Growth, Pharmaceutical industry

Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.

Key Points: 
  • Onera Health, pioneer and leader in remote sleep diagnostic and monitoring solutions enabling clinicians to conduct sleep studies anytime, anywhere, announced the completion of its Series C financing round.
  • This latest funding round brings Onera’s total investment to date to more than €55 million.
  • View the full release here: https://www.businesswire.com/news/home/20240115279169/en/
    Ruben de Francisco, Founder and CEO of Onera Health.
  • As part of this transaction, Drew Burdon and Michaël Vlemmix will join Onera Health’s Board of Directors.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Saturday, January 13, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

EQS-News: Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.

Retrieved on: 
Saturday, January 13, 2024
Record, DACH, Pharmacy, International, Sevenum, EUR, Annual report, Growth, Lithium

Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.

Key Points: 
  • Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.
  • Another successful fast-growth quarter for Redcare Pharmacy, completing full year 2023 at the very upper end of its guidance.
  • Full year total sales EUR 1.8bn vs. guidance of EUR 1.7-1.8bn, a growth of 49%.
  • In full year 2023, growth in International stood at 31%, with sales at EUR 345 million (FY 2022: EUR 264 million).

Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Tuesday, January 9, 2024
DACH, Incidence, Senior counsel, NPV, Cancer, Algorithm, BGM, EMERGE, CRC, Ministry of Social Affairs, AA, Growth, Collection, Labour, Marketing, PMA, PCR, Education, Physician, Death, Colorectal cancer, AI, Commercial, Genetic testing, Gold, Laboratory, PPV, Therapy, Machine learning, Gene expression, Ageing, Mortality, Patient, Hospital, Traction, Health, Partnership, PHI, FG, Big Pharma, Food, FDA, Biomarker, United Nations, Messenger, Clinical trial, Pancreatic cancer, Pharmaceutical industry

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

DigitalBridge Strengthens Commitment to European Region with Hiring of Ersin Yorulmaz as Co-Head of European Capital Formation

Retrieved on: 
Monday, January 8, 2024
Technology, Networks, Internet, Data Management, Yorulmaz, Ersin, Capital formation, Acquisition, DigitalBridge, BlackRock, Consultant, Growth, Investment, LP record, CFA, DACH, Renewable energy

DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) today announced it has hired Ersin Yorulmaz as Managing Director, Co-Head of European Capital Formation, effective immediately.

Key Points: 
  • DigitalBridge Group, Inc. (NYSE: DBRG) (“DigitalBridge”) today announced it has hired Ersin Yorulmaz as Managing Director, Co-Head of European Capital Formation, effective immediately.
  • He assumes the role alongside Alice Franks, who was appointed Head of European Capital Formation in February 2023.
  • Yorulmaz brings over 10 years of experience in capital formation, along with deep expertise in the DACH market.
  • “We are delighted to welcome Ersin at such an exciting time for DigitalBridge in the DACH region,” said Kevin Smithen, Chief Commercial and Strategy Officer at DigitalBridge.

EQS-News: GRENKE CONTINUES ITS PROFITABLE GROWTH PATH: EUR 2.6 BILLION IN NEW LEASING BUSINESS IN 2023

Retrieved on: 
Thursday, January 4, 2024
DACH, CM2, Face, Growth, EUR, Investment, Baden-Baden, Film industry

GRENKE CONTINUES ITS PROFITABLE GROWTH PATH: EUR 2.6 BILLION IN NEW LEASING BUSINESS IN 2023

Key Points: 
  • GRENKE CONTINUES ITS PROFITABLE GROWTH PATH: EUR 2.6 BILLION IN NEW LEASING BUSINESS IN 2023
    The issuer is solely responsible for the content of this announcement.
  • GRENKE continues its profitable growth path: EUR 2.6 billion in new leasing business in 2023
    New leasing business in 2023 surpasses previous year's level by 12.3 % (2022: EUR 2.3 billion) and reaches the lower end of 2023 forecast
    CM2 increases by 15.3 % to EUR 426.3 million (2022: EUR 369.6 million)
    CM2 margin rises to 16.5 % (2022: 16.1 %)
    Baden-Baden, January 4, 2024: GRENKE AG, a global financing partner for small and medium-sized enterprises, continued on its double-digit growth path.
  • At EUR 729.7 million, new leasing business in the fourth quarter of 2023 was 12.8 % higher year-on-year (Q4 2022: EUR 647.0 million).
  • GRENKE Bank's new lending business, which largely consists of the microcredit business, totalled EUR 11.6 million in the fourth quarter of 2023 (Q4 2022: EUR 10.1 million).